Summary of Pharvaris Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Industry**: Hereditary Angioedema (HAE) therapeutics - **Focus**: Development of therapies for bradykinin-mediated angioedema, including prophylactic and on-demand treatment options [1][2][3] Core Points and Arguments Market Evolution - The HAE market has evolved significantly over the past 20 years, transitioning from a focus on managing attacks to controlling the disease [8][9] - Current market size for on-demand treatment is estimated at **$600 million** in the US, representing about **20%** of the total HAE market [29][46] - The market is expected to be dominated by oral therapies due to their simplicity and speed of treatment [29][31] Product Development and Clinical Trials - Pharvaris is developing **deucrictibant**, with Phase 3 data showing statistically significant results across all primary and secondary endpoints [16][17] - Key Phase 3 endpoint results include: - Time to initial symptom relief: **1.28 hours** - Time to stop attack progression: **17.5 minutes** - Time to complete symptom resolution: less than **12 hours** [16][17] - The company is also conducting a Phase 3 trial for prophylactic treatment (CHAPTER-3) with top-line data expected in Q3 of this year [54][56] Patient Experience and Market Strategy - The convenience of an oral treatment is emphasized as a significant factor for patients, allowing for immediate use during an attack [20][22] - The company aims to provide a therapy that not only alleviates symptoms but also enhances the quality of life for patients [61] - Pharvaris is building awareness in the HAE community through campaigns like "Deflate HAE" and is preparing for product launches [52][100] Competitive Landscape - The current competitive landscape includes products like **icatibant** and **Orladeyo**, with Pharvaris aiming to offer a more effective oral alternative [28][46][49] - The company believes that a successful launch of deucrictibant could shift market dynamics, potentially leading to a return to branded pricing for on-demand treatments [48][49] Financial Position and Future Outlook - Pharvaris has a strong cash position with **EUR 360 million** reported in Q3, providing a runway into the first half of 2027 [107][108] - Upcoming catalysts include the NDA filing for on-demand treatment and the potential for a joint filing for prophylactic treatment [103][104] Additional Important Insights - The company is exploring opportunities in acquired angioedema, which is currently underdiagnosed and represents about **10%** of the market [71][75] - There is a strategic advantage in offering both on-demand and prophylactic options, allowing for flexibility in patient treatment plans [82][85] - The company is focused on building relationships with healthcare providers to facilitate the adoption of their therapies [100][101]